Cell therapies for immune-mediated disorders DOI Creative Commons
Natalia Krata, Bartosz Foroncewicz, Krzysztof Mucha

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 26, 2025

Immune-mediated disorders are a broad range of diseases, arising as consequence immune defects, exaggerated/misguided response or mixture both conditions. Their frequency is on rise in the developed societies and they pose significant challenge for diagnosis treatment. Traditional pharmacological, monoclonal antibody-based polyclonal antibody replacement-based therapies aiming at modulation responses give very often dissatisfactory results and/or burdened with unacceptable adverse effects. In recent years, new group treatment modalities has emerged, utilizing cells living drugs, especially use up-to-date genetic engineering. These modern cellular designed to offer high potential more targeted, safe, durable, personalized options. This work briefly reviews latest advances immune-mediated disorders, mainly those related exaggeration response, such hematopoietic stem (HSCs), mesenchymal stromal (MSCs), regulatory T (Tregs), chimeric antigen receptor (CAR) others. We highlight main features these options taming dysregulated system. Undoubtfully, near future can provide lasting remissions reduced burden improved quality life patients.

Language: Английский

Cell therapies for immune-mediated disorders DOI Creative Commons
Natalia Krata, Bartosz Foroncewicz, Krzysztof Mucha

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 26, 2025

Immune-mediated disorders are a broad range of diseases, arising as consequence immune defects, exaggerated/misguided response or mixture both conditions. Their frequency is on rise in the developed societies and they pose significant challenge for diagnosis treatment. Traditional pharmacological, monoclonal antibody-based polyclonal antibody replacement-based therapies aiming at modulation responses give very often dissatisfactory results and/or burdened with unacceptable adverse effects. In recent years, new group treatment modalities has emerged, utilizing cells living drugs, especially use up-to-date genetic engineering. These modern cellular designed to offer high potential more targeted, safe, durable, personalized options. This work briefly reviews latest advances immune-mediated disorders, mainly those related exaggeration response, such hematopoietic stem (HSCs), mesenchymal stromal (MSCs), regulatory T (Tregs), chimeric antigen receptor (CAR) others. We highlight main features these options taming dysregulated system. Undoubtfully, near future can provide lasting remissions reduced burden improved quality life patients.

Language: Английский

Citations

0